Short Communication: A Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study

Authors

• David M. MacDonald, Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
• Gary Collins, Division of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA.
• Chris H. Wendt, Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota, Minneapolis, Minnesota, USA.
• Julian Wolfson, Division of Biostatistics, University of Minnesota, Minneapolis, Minnesota, USA.
• Russell P. Tracy, Department of Pathology and Laboratory Medicine, University of Vermont, Burlington, Vermont, USA.
• Frank Rhame, Division of Infectious Diseases, Hennepin County Medical Center, Minneapolis, Minnesota, USA.
• Steven Deeks, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
• Stacey A. Rizza, Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
• Zelalem Temesgen, Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.
• Caryn Morse, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
• Angelike P. Liappis, Washington DC Veterans Affairs Medical Center, Section of Infectious Diseases and The George Washington University, Washington, District of Columbia, USA.
• Irini Sereti, HIV Pathogenesis Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
• Jason V. Baker, Division of Infectious Diseases, Hennepin County Medical Center, Minneapolis, Minnesota, USA.
• Ken M. Kunisaki, Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, University of Minnesota, Minneapolis, Minnesota, USA.

Document Type

Journal Article

Publication Date

2-1-2022

Journal

AIDS research and human retroviruses

Volume

38

Issue

2

DOI

10.1089/AID.2020.0285

Keywords

HIV; angiotensin receptor antagonists; biomarkers; lung diseases; pulmonary surfactant-associated protein D; uteroglobulin

Abstract

HIV is an independent risk factor for lung disease, including chronic obstructive pulmonary disease (COPD) and emphysema. Angiotensin receptor blockers may be beneficial in COPD and emphysema through pathways that have been implicated in HIV-related lung disease. We performed a randomized comparison of the effects of losartan versus placebo on the plasma concentrations of the pneumoproteins, surfactant protein D (SPD) and club cell secretory protein (CCSP), in people living with HIV (PLWH). A total of 108 PLWH were included (52 assigned to losartan and 56 assigned to placebo). We found no difference in the change from baseline in log concentrations of CCSP or SPD over 1 year of follow-up. For SPD, we found a strong interaction by CD4+ counts, where those with CD4+ counts >350 cells/mm treated with losartan had more reduction (improvement) in SPD concentration than those treated with placebo ( value for interaction <.001). In conclusion, we did not find a beneficial effect of losartan on pneumoprotein concentrations in PLWH, but PLWH with higher CD4+ counts may have improvement in SPD when treated with losartan.

APA Citation

MacDonald, David M.; Collins, Gary; Wendt, Chris H.; Wolfson, Julian; Tracy, Russell P.; Rhame, Frank; Deeks, Steven; Rizza, Stacey A.; Temesgen, Zelalem; Morse, Caryn; Liappis, Angelike P.; Sereti, Irini; Baker, Jason V.; and Kunisaki, Ken M., "Short Communication: A Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study" (2022). GW Authored Works. Paper 335.
https://hsrc.himmelfarb.gwu.edu/gwhpubs/335

Department

Microbiology, Immunology, and Tropical Medicine